Carisma Therapeutics (CARM) Competitors

Coeptis Therapeutics (NASDAQ:COEP) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.

Does the MarketBeat Community favor COEP or CARM?

Carisma Therapeutics received 13 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. Likewise, 78.26% of users gave Carisma Therapeutics an outperform vote while only 71.43% of users gave Coeptis Therapeutics an outperform vote.

Company	Underperform	Outperform
Coeptis Therapeutics	Outperform Votes 5 71.43%	Underperform Votes 2 28.57%
Carisma Therapeutics	Outperform Votes 18 78.26%	Underperform Votes 5 21.74%

Which has more risk & volatility, COEP or CARM?

Coeptis Therapeutics has a beta of -0.59, meaning that its share price is 159% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in COEP or CARM?

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 12.6% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better valuation and earnings, COEP or CARM?

Coeptis Therapeutics has higher earnings, but lower revenue than Carisma Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$62.87K	469.47	-$21.27M	-$5.80	-1.45
Carisma Therapeutics	$19.96M	1.15	-$86.88M	-$1.56	-0.35

Do analysts rate COEP or CARM?

Carisma Therapeutics has a consensus price target of $1.93, suggesting a potential upside of 251.15%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Carisma Therapeutics	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.43

Is COEP or CARM more profitable?

Coeptis Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Carisma Therapeutics' return on equity of -957.20% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%
Carisma Therapeutics	-314.78%	-957.20%	-96.39%

Does the media prefer COEP or CARM?

In the previous week, Carisma Therapeutics had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Carisma Therapeutics and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.87 beat Carisma Therapeutics' score of 0.52 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coeptis Therapeutics	Very Positive
Carisma Therapeutics	Positive

Summary

Carisma Therapeutics beats Coeptis Therapeutics on 14 of the 19 factors compared between the two stocks.